Diosbulbin B
Based on 1 publication(s) in Google Scholar
Diosbulbin B, a diterpene lactone, is an anticancer agent. Diosbulbin B is an orally active component of Dioscorea. bulbifera L. Diosbulbin B can inhibit cell proliferation, induce G0/G1 phase arrest and apoptosis. Diosbulbin B can induce autophagy and mitochondrial dysfunction. Diosbulbin B can induce liver injury. Diosbulbin B can be used for the research of cancer, such as non-small cell lung cancer (NSCLC).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.90%
- CAS No.: 20086-06-0
- Formule: C19H20O6
- Masse moléculaire:344.36
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Diosbulbin B
More
Activité biologique
Description
In Vitro
Diosbulbin B (0.5-400 μM, 24-72 h) inhibits proliferation in A549 and PC-9 cells, with IC50 values of 44.61 and 22.78 μM, respectively[1].
Diosbulbin B (12.5-100 μM, 24 h) enhances the ratio of cells in the G0/G1 phase in A549 and PC-9 cells[1].
Diosbulbin B (12.5-100 μM, 48 h) induces apoptosis in A549 and PC-9 cells[1].
Diosbulbin B (12.5-100 μM, 48 h) inhibits colony formation in A549 and PC-9 cells[1].
Diosbulbin B (12.5-100 μM, 48 h) reduces the levels of YY1 and apoptosis-related proteins and increases p53 levels in A549 and PC-9 cells[1].
Diosbulbin B (50-200 μM, 48h) induces autophagy and apoptosis in L-02 hepatocytes[3].
Diosbulbin B (50-200 μM, 48 h) causes mitochondrial dysfunction in L-02 hepatocytes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 and PC-9 cells
-
Concentration:12.5, 25, 50 and 100 μM
-
Incubation Time:24 h
-
Result:Markedly enhanced the ratio of cells in the G0/G1 phase.
Decreased the proportion of cells in the S phase and G2/M phase.
-
Cell Line:A549 and PC-9 cells
-
Concentration:12.5, 25, 50 and 100 μM
-
Incubation Time:48 h
-
Result:Reduced the level of YY1 protein and increased p53 levels.
Suppressed the expression of Cyclin A2 and B2, along with the CDK1, CDK2, CDK4 and BCL-2.
-
Cell Line:L-02 hepatocytes
-
Concentration:50, 100 and 200 μM
-
Incubation Time:48 h
-
Result:Increased LC3 II/I and Beclin-1 levels and decreased P62 levels.
Enhanced protein expression of Bax and up-regulated activities of caspase-3 and caspase-9.
In Vivo
Diosbulbin B (16-64 mg/kg, i.g., daily for 12 days) induces liver injury in ICR mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Xenograft A549 tumor mice models[1]
-
Dosage:5 and 15 mg/kg
-
Administration:Intraperitoneally injection, daily for 2 weeks
-
Result:Reduced tumor volume and weight.
Did not result in any alterations in both body weight and organ coefficient.
Induced tumor cells disorganized and underwent apoptosis.
Reduced the level of YY1 protein and increased p53 levels.
Suppressed the expression of Cyclin A2 and B2, along with the CDK1, CDK2, and CDK4.
-
Animal Model:ICR mice (male, 18-22 g)[2]
-
Dosage:16, 32 and 64 mg/kg
-
Administration:Orally gavage, daily for 12 days
-
Result:Increased the values of ALT, AST, ALP and MDA.
Lost normal architecture inliver.
Reduced glutathione levels and GST, GPx, SOD and CAT activities.
Chemical Information
-
CAS No. 20086-06-0
-
Appearance Solid
-
Masse moléculaire 344.36
-
Formule C19H20O6
-
Color White to off-white
-
SMILES
O=C1[C@]23C[C@H](O1)[C@]4([H])[C@H]5C[C@H](OC5=O)C[C@@]4([H])[C@]2(C)C[C@H](C6=COC=C6)O3
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvant et solubilité
In Vitro:
DMSO : 14.29 mg/mL (41.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.33 mg/mL (3.86 mM); Clear solution
This protocol yields a clear solution of ≥ 1.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (13.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.33 mg/mL (3.86 mM); Clear solution
This protocol yields a clear solution of ≥ 1.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (13.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (287 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhao JQ, et al. The anti-non-small cell lung cancer effect of Diosbulbin B: Targeting YY1 induced cell cycle arrest and apoptosis. Phytomedicine. 2024 Jul 25;130:155734. [Content Brief]
[2]. Ma Y, et al. Diosbulbin B-induced liver injury in mice and its mechanism. Hum Exp Toxicol. 2014 Jul;33(7):729-36. [Content Brief]
[3]. Ye J, et al. Diosbulbin B-Induced Mitochondria-Dependent Apoptosis in L-02 Hepatocytes is Regulated by Reactive Oxygen Species-Mediated Autophagy. Front Pharmacol. 2019 Jun 19;10:676. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9039 mL | 14.5197 mL | 29.0394 mL | 72.5984 mL |
| 5 mM | 0.5808 mL | 2.9039 mL | 5.8079 mL | 14.5197 mL | |
| 10 mM | 0.2904 mL | 1.4520 mL | 2.9039 mL | 7.2598 mL | |
| 15 mM | 0.1936 mL | 0.9680 mL | 1.9360 mL | 4.8399 mL | |
| 20 mM | 0.1452 mL | 0.7260 mL | 1.4520 mL | 3.6299 mL | |
| 25 mM | 0.1162 mL | 0.5808 mL | 1.1616 mL | 2.9039 mL | |
| 30 mM | 0.0968 mL | 0.4840 mL | 0.9680 mL | 2.4199 mL | |
| 40 mM | 0.0726 mL | 0.3630 mL | 0.7260 mL | 1.8150 mL |
Diosbulbin B Related Classifications
HY-N0429 Related Classifications
Powered by Bioz